Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night ...
May 16 2019 - 1:05PM
Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader
in the growing field of cancer metabolism-based therapeutics,
announced today that Sanjeev Luther, President and Chief Executive
Officer, was named the 2019 Corporate Honoree by the American
Cancer Society (ACS). This prestigious honor will be given to Mr.
Luther on May 18th at the 12th Annual Starry Night Gala.
Mr. Luther’s passion for driving cancer research
can be reflected in the success he has made at Rafael
Pharmaceuticals. The company is developing a new, first-in-class
category of metabolic oncology therapeutics that attacks
hard-to-treat cancers by targeting the metabolic processes the
disease needs to survive, grow and proliferate. Under Mr. Luther’s
leadership, Rafael has made significant progress in its clinical
development, including two Phase 3 programs of its lead molecule
CPI-613® (devimistat) for patients with metastatic pancreatic
cancer and relapsed or refractory acute myeloid leukemia (AML) and
several orphan designations. Mr. Luther also brings thirty years of
experience to Rafael from leading Fortune 500 pharmaceutical
companies.
“I would like to thank the ACS for this truly
humbling honor,” said Mr. Luther. “It is because of the
researchers, leaders, volunteers and staff at the ACS that there is
hope for patients, survivors and families. Together, with ACS and
the passionate team at Rafael, I believe that we will continue to
positively impact lives and make advancements for future
generations as we live by Rafael's motto, ‘To Save A Life Is
To Save A Universe.’”
The Starry Night Gala is held each year to
celebrate the accomplishments of the ACS and to look forward to
future successes by raising money for more research, treatment
options, and survivors. It is attended by healthcare professionals,
top business leaders and philanthropic individuals. Honorees, or
“Inspirers of Hope,” are recognized each year for their dedication
to cancer research, cancer treatment and cancer recovery. Mr.
Luther will be one of four honorees recognized at this year’s
event.
About Rafael Pharmaceuticals,
Inc.Rafael Pharmaceuticals, Inc. is clinical stage company
and a leader in the growing field of cancer metabolism-based
therapeutics. Rafael’s primary objective is to develop and
commercialize innovative, highly selective, well tolerated and
highly effective anti-cancer agents by selectively targeting the
altered metabolism in cancer cells. Rafael’s first-in-class
clinical lead compound, CPI-613®(devimistat), is being evaluated in
multiple ongoing/completed Phase I, II, and III clinical studies.
CPI-613®(devimistat) has been granted orphan drug designation for
the treatment of Pancreatic Cancer, Acute Myeloid Leukemia (AML),
Peripheral T-Cell Lymphoma (PTCL), Burkitt Lymphoma and
Myelodysplastic Syndromes (MDS). Rafael Pharmaceuticals is an
affiliate of Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more
information, visit http://www.rafaelpharma.com/.
Safe Harbor StatementThis press
release contains forward-looking statements. These statements
relate to future events or the company’s future financial
performance. In some cases, you can identify forward-looking
statements by terminology such as "may", "will", "should",
"expect", "plan", "anticipate", "believe", "estimate", "predict",
"potential" or "continue", the negative of such terms, or other
comparable terminology. These statements are only predictions.
Actual events or results may differ materially from those in the
forward-looking statements as a result of various important
factors. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, such statements should
not be regarded as a representation by the company, or any other
person, that such forward-looking statements will be achieved. The
business and operations of the company are subject to substantial
risks which increase the uncertainty inherent in forward-looking
statements. We undertake no duty to update any of the
forward-looking statements, whether as a result of new information,
future events or otherwise.
In light of the foregoing, readers are cautioned
not to place undue reliance on such forward-looking statements.
###
Company Contact:Sanjeev
LutherPresident & CEO Rafael Pharmaceuticals, Inc.
sanjeev.luther@rafaelpharma.com
Media Contact:Vanessa
Donohuerafael@antennagroup.com 201-465-8036
Rafael (NYSE:RFL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rafael (NYSE:RFL)
Historical Stock Chart
From Apr 2023 to Apr 2024